{"id":5663,"date":"2014-12-15T09:00:00","date_gmt":"2014-12-15T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/"},"modified":"2024-09-23T11:22:41","modified_gmt":"2024-09-23T11:22:41","slug":"nieuwe-glucagon-succesvol-getest","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/","title":{"rendered":"Nieuwe glucagon succesvol getest"},"content":{"rendered":"\"icoon<\/a>Een van de oplossingspaden van Breakthrough T1D is de kunstmatige alvleesklier. Het doel hiervan is de ontwikkeling van een systeem dat de biologische functie van de alvleesklier nabootst. Hierdoor wordt de dagelijkse impact van Type 1 Diabetes (T1D) vermindert.\n\nEen volledig functionele kunstmatige alvleesklier werkt met insuline en glucagon. De insuline zorgt ervoor dat de gemeten bloedsuikerwaarde omlaag wordt gebracht. Glucagon moet ervoor zorgen dat te lage bloedsuikerwaardes weer omhoog kunnen worden gestuurd. Echter, tot voor kort was er geen glucagon beschikbaar die hiervoor gebruikt kon worden.<\/span>\n
\n\nGlucagon is een instabiel stofje. Je kent het vast wel: dat oranje doosje in de koelkast dat je hopelijk nog nooit hebt hoeven gebruiken. De huidige versie werkt met twee delen: een ampul en een injectiespuit. Je moet verschillende handelingen volbrengen voordat je de glucagon kan inspuiten bij een te lage bloedsuikerwaarde. Hierdoor is deze vorm van glucagon niet geschikt voor een kunstmatige alvleesklier.\n\nNu heeft Breakthrough T1D partner Xeris een stabiele, vloeibare glucagon ontwikkeld die in een kunstmatige alvleesklier gebruikt kan worden. In een eerste ronde klinische tests is nu gekeken of het product veilig is, hoe snel het wordt opgenomen en of het product net zo goed werkt als de huidige glucagon pen.\n\nDe G-pump glucagon bleek net zo goed te werken als de glucagon pen. Dit resultaat is een grote stap vooruit op weg naar een volledig functionele, geautomatiseerde kunstmatige alvleesklier.\n\n<\/div>","protected":false,"raw":""},"excerpt":{"rendered":"

Een van de oplossingspaden van Breakthrough T1D is de kunstmatige alvleesklier. Het doel hiervan is de ontwikkeling van een systeem dat de biologische functie van de alvleesklier nabootst. Hierdoor wordt de dagelijkse impact van Type 1 Diabetes (T1D) vermindert. Een volledig functionele kunstmatige alvleesklier werkt met insuline en glucagon. De insuline zorgt ervoor dat de […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184],"tags":[],"class_list":["post-5663","post","type-post","status-publish","format-standard","hentry","category-archief"],"yoast_head":"\nNieuwe glucagon succesvol getest - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nieuwe glucagon succesvol getest - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Een van de oplossingspaden van Breakthrough T1D is de kunstmatige alvleesklier. Het doel hiervan is de ontwikkeling van een systeem dat de biologische functie van de alvleesklier nabootst. Hierdoor wordt de dagelijkse impact van Type 1 Diabetes (T1D) vermindert. Een volledig functionele kunstmatige alvleesklier werkt met insuline en glucagon. De insuline zorgt ervoor dat de […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2014-12-15T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/icoon-kunstmatige-alvleesklier-150x150-2.jpg\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Nieuwe glucagon succesvol getest\",\"datePublished\":\"2014-12-15T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/\"},\"wordCount\":237,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/icoon-kunstmatige-alvleesklier-150x150-2.jpg\",\"articleSection\":[\"Archief\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/\",\"name\":\"Nieuwe glucagon succesvol getest - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/icoon-kunstmatige-alvleesklier-150x150-2.jpg\",\"datePublished\":\"2014-12-15T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nieuwe glucagon succesvol getest\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nieuwe glucagon succesvol getest - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/","og_locale":"nl_NL","og_type":"article","og_title":"Nieuwe glucagon succesvol getest - Breakthrough T1D","og_description":"Een van de oplossingspaden van Breakthrough T1D is de kunstmatige alvleesklier. Het doel hiervan is de ontwikkeling van een systeem dat de biologische functie van de alvleesklier nabootst. Hierdoor wordt de dagelijkse impact van Type 1 Diabetes (T1D) vermindert. Een volledig functionele kunstmatige alvleesklier werkt met insuline en glucagon. De insuline zorgt ervoor dat de […]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/","og_site_name":"Breakthrough T1D","article_published_time":"2014-12-15T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:41+00:00","og_image":[{"url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/icoon-kunstmatige-alvleesklier-150x150-2.jpg","type":"","width":"","height":""}],"author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Nieuwe glucagon succesvol getest","datePublished":"2014-12-15T09:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/"},"wordCount":237,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#primaryimage"},"thumbnailUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/icoon-kunstmatige-alvleesklier-150x150-2.jpg","articleSection":["Archief"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/","name":"Nieuwe glucagon succesvol getest - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#primaryimage"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#primaryimage"},"thumbnailUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/icoon-kunstmatige-alvleesklier-150x150-2.jpg","datePublished":"2014-12-15T09:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-glucagon-succesvol-getest\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Nieuwe glucagon succesvol getest"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5663"}],"version-history":[{"count":3,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5663\/revisions"}],"predecessor-version":[{"id":8005,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5663\/revisions\/8005"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}